Item 1.01 Entry into a Material Definitive Agreement

On November 1, 2021, Corvus Pharmaceuticals, Inc. (the "Company") entered into an Open Market Sales Agreement (the "Sales Agreement") with Jefferies LLC ("Jefferies") to sell shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), with aggregate gross sales proceeds of up to $40,000,000, from time to time, through an "at the market" equity offering program under which Jefferies will act as sales agent.

Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made and any minimum price below which sales may not be made. Subject to the terms and conditions of the Sales Agreement, Jefferies may sell the shares (a) in privately negotiated transactions with the consent of the Company; (b) as block transactions; or (c) by any other method permitted by law deemed to be an "at the market" offering as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, including sales made through The Nasdaq Global Market or any other trading market for our common stock. In addition, Jefferies may also sell shares to Jefferies acting as principal for Jefferies' own account. Jefferies will use its commercially reasonable efforts in conducting such sales activities consistent with its normal trading and sales practices. Jefferies and the Company each have the right, by giving written notice as specified in the Sales Agreement, to terminate the Sales Agreement in each party's sole discretion at any time.

The Sales Agreement provides that Jefferies will be entitled to compensation for its services of up to 3.0% of the gross proceeds of any shares of common stock sold through Jefferies under the Sales Agreement. Jefferies and the Company have no obligation to sell any shares under the Sales Agreement and may at any time suspend any sale under the Sales Agreement.

The shares will be issued pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-237040). The Company filed a prospectus supplement, dated November 1, 2021 with the Securities and Exchange Commission in connection with the offer and sale of the shares pursuant to the Sales Agreement.

The foregoing description of the material terms of the Sales Agreement is qualified in its entirety by reference to the full agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The legal opinion of Latham & Watkins LLP relating to the shares of Common Stock that may be sold pursuant to Sales Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K.

This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of any offer to buy the securities discussed herein, nor shall there be any offer, solicitation or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Item 9.01 Financial Statements and Exhibits.






Exhibit                                                  Incorporated by Reference        Filed
Number               Exhibit Description               Form       Date        Number     Herewith

  1.1        Sales Agreement, dated as of                                                   X
           November 1, 2021, between Corvus
           Pharmaceuticals, Inc. and Jefferies
           LLC.

  5.1        Opinion of Latham & Watkins LLP.                                               X

  23.1       Consent of Latham & Watkins LLP                                                X
           (included in Exhibit 5.1).

104        Cover Page Interactive Data File
           (embedded within the Inline XBRL
           document)

© Edgar Online, source Glimpses